

Increasing Attention on KPD – Flatbush Diabetes

¹Afrânio Côgo Destefani, ²Trevenzoli, R. M.

Abstract: Ketosis-prone diabetes (KPD) or "atypical diabetes," "Flatbush diabetes," "diabetes type 1B," and "ketosis-inclined type 2 diabetes mellitus" is a boundless, developing, heterogeneous disorder portrayed by patients who give diabetic ketoacidosis or ridiculous ketosis however don't really have the average phenotype of immune system type 1 diabetes. Numerous, serious types of β -cell brokenness seem to underlie the pathophysiology of KPD. Up to this point, the disorder has did not have an exact, clinically pertinent and etiologically helpful arrangement conspire. The predominance of KPD is rising. Insulinopaenia at presentation requires escalated insulin treatment at conclusion; nevertheless, these people display a test to medicinal services experts as to how their diabetes ought to be overseen over the more extended term. With the chance to stop insulin treatment and with the presentation of oral hypoglycaemic specialists, trust in dealing with this gathering of individuals is developing. The lynchpin for foreseeing the clinical course of KPD and helping in the choice to stop insulin is evaluation of islet cell autoantibodies and beta-cell work, and the utilization of the A β arrangement of order appears to precisely give clinicians the biochemical bolster that, thusly, will make us more positive about dealing with these people.

Keywords: Ketosis-prone diabetes; Islet cell autoantibodies; diabetes mellitus.

1. INTRODUCTION

Since the mid-1990s expanding consideration has been centered around, a heterogeneous condition described by presentation with diabetic ketoacidosis (DKA) in patients who do not really fit the average attributes of immune system type 1 diabetes. Prior reports utilized the expressions "atypical diabetes," "Flatbush diabetes," "diabetes type 1B," and "ketosis-inclined type 2 diabetes mellitus" to depict subsets of this condition, and it was noticed that in a few occasions patients gave DKA as the principal sign of diabetes and developed to insulin-freedom^{1,2}. While at first these reports proposed that the condition, now named ketosis prone diabetes (KPD), may be constrained to people of non-Caucasian ethnicity, its commonness gives off an impression of being expanding overall³⁻²⁸.

The order, pathophysiology, normal history, and administration of KPD will be inspected here. Patients with islet autoantibodies who don't present with ketosis, including those named "latent autoimmune diabetes in adults" (LADA), "type 1.5 diabetes"^{29,30}, and "slowly progressing type 1 diabetes"³¹ are talked about somewhere else.

2. CLASSIFICATION OF KPD

KPD involves a gathering of atypical diabetes disorders described by extreme beta cell brokenness (showed by presentation with DKA or unwarranted ketosis) and a variable clinical course. These disorders do not fit the conventional classifications of diabetes characterized by the American Diabetes Association (ADA). To date, endeavors to separate patients with KPD into clinically particular subgroups have brought about four distinctive characterization plots: the ADA system, a changed ADA system, a BMI-based system, and the A β system. The objective of new grouping plans is to empower clinicians to anticipate which patients with DKA require impermanent insulin treatment versus deep-rooted insulin treatment. They additionally highlight subgroups for further hereditary and pathogenetic thinks about. In a longitudinal review looking at the four grouping plans for precision and prescient esteem, the A β system was appeared to be the most exact in foreseeing long haul insulin reliance 12 months after the record DKA occasion, with 99 percent affectability and 96 percent specificity^{5,32}.

2.1. ADA system:

In the ADA characterization, type 1 diabetes is described via immune system obliteration of the pancreatic beta cells, prompting to total insulin insufficiency. Markers of invulnerable interceded diabetes incorporate antibodies to glutamic acid decarboxylase (GAD) and to the tyrosine phosphatase IA-2. Among patients giving DKA (total insulin inadequacy), the individuals who need autoantibodies are alluded to as "idiopathic type 1" or "type 1b"; the last incorporates patients with the clinical appearance of type 2 diabetes, with some getting to be insulin-autonomous.

2.2. Modified ADA system:

A change of the ADA plan is used by agents in France, who partition KPD patients into three gatherings²³. Patients with beta cell autoantibodies are delegated type 1a similarly as in the ADA plot, while the individuals who need autoantibodies are recognized reflectively, in view of long haul insulin reliance, into "KPD insulin dependent" (KPD-ID) and "KPD non-insulin dependent" (KPD-NID). Both type 1a and KPD-ID patients have clinical attributes of type 1 diabetes with poor beta cell work, while subjects with KPD-NID have clinical qualities of type 2 diabetes with safeguarded beta cell work for a delayed term.

2.3. BMI system:

The BMI-based plan isolates KPD patients into incline ($BMI < 28 \text{ kg/m}^2$, clinically looking like type 1 with low beta cell work) or fat ($BMI \geq 28 \text{ kg/m}^2$, clinically taking after type 2 with protected beta cell work)¹².

2.4. A β system:

The community oriented gathering at Baylor College of Medicine and the University of Washington use a grouping framework (A β order) that recognizes four KPD subgroups in light of the nearness or nonappearance of autoantibodies and the nearness or nonattendance of beta cell utilitarian save, as measured by a fasting or glucagon - animated C-peptide level⁴. The four subgroups are characterized as takes after:

- A+ β - autoantibodies present, beta cell function absent
- A+ β + autoantibodies present, beta-cell function present
- A- β - autoantibodies absent, beta cell function absent
- A- β + autoantibodies absent, beta cell function present

A+ β - and A- β - patients are immunologically and hereditarily particular from each other however share clinical qualities of type 1 diabetes with diminished beta cell work, and both subgroups would be named type 1 diabetes (type 1 and 1b) in the present ADA grouping framework. A+ β + and A- β + patients are immunologically and hereditarily unmistakable from each other however share clinical attributes of type 2 diabetes with protected beta cell utilitarian save and would be named type 2 diabetes in the ADA plot. A- β + patients include the biggest KPD subgroup (roughly 50 percent) in multiethnic accomplices of KPD patients in the United States (table 1)³³. They are additionally the patients who most normally gone to the notice of clinicians since they give DKA yet have the clinical elements and resulting conduct of type 2 diabetes^{1,4,34}. In light of a legitimate concern for characterizing and exploring novel disorders of beta cell brokenness, the more extensive phrasing of "ketosis-inclined diabetes" with its four subgroups subsumed under the A β arrangement, as opposed to ketosis-inclined type 2 diabetes, is more helpful and it doesn't attempt to characterize a disorder from the earlier.

3. PATHOPHYSIOLOGY OF KDP SYNDROMES**3.1. Autoantibodies present, beta cell function absent or present:**

There is a range of beta cell annihilation in patients with immune response positive diabetes. Recognizing A+ β - from A+ β + KPD licenses agents to investigate diverse immune system pathways prompting to clinically particular examples of beta cell misfortune, for example, unique latencies and variable degrees of beta cell pulverization. The later onset and more direct clinical course (capacity to suspend insulin for more than two years taking after the file scene of DKA in 50 percent of the patients) of A+ β + KPD contrasted with A+ β -KPD seems; by all accounts, to be connected to a limited extent to epitope-particular antibodies to the 65-kDa isoform of glutamic acid decarboxylase (GAD65). A particular

amino-terminal epitope characterized by monoclonal immune response DPD related with higher beta cell useful save and was connected with the milder A+β+ phenotype³⁵. The instruments that outcome in this autoantibody specificity and offer ascent to variable beta cell useful save stay to be explained.

3.2. Autoantibodies and beta cell function absent:

A-β-KPD is portrayed by beta cell disappointment without confirmation of autoimmunity. Some A-β-KPD patients may have untested autoantibodies, for example, those against the zinc transporter (ZnT8)³⁶ or SOX13 (SRY-related HMG box antigen 13)³⁷. On the other hand, some A-β-KPD patients might be misclassified as "A-" in light of a decrease in autoantibody titers after some time. In one associate, just 10 percent of patients who were A-β-had new-onset diabetes when recognized at presentation with DKA; the greater part had insulin-subordinate diabetes for a long time beforehand⁴.

Be that as it may, a decrease in immune response titer is more outlandish as GAD autoantibodies are accounted for to be very sturdy³⁸⁻⁴⁰. Also, broad HLA writing uncovers that the frequencies of real class II alleles connected with vulnerability to immune system type 1 diabetes are not essentially higher in A-β-KPD patients than in ethnic-coordinated populace controls, though they are fundamentally higher in A+β-KPD patients, recommending huge contrasts in the two populaces⁴¹.

The solid family history of diabetes in relatives of A-β-KPD proposes that there is a familial characteristic and that qualities required for beta cell advancement, recovery, or capacity might be included. Possibly critical variations in the qualities TCF1, PAX-4, and PDX-1, encoding the key beta cell interpretation variables hepatocyte atomic element 1alpha (HNF1a), PAX-4, and pancreas-duodenum homeobox-1 (PDX-1), are improved in A-β-KPD patients contrasted with ethnic-particular populace controls; these may add to the A-β-phenotype⁴².

3.3. Autoantibodies absent, beta cell function present:

The A-β+ phenotype is described by halfway reversible beta cell brokenness, which might be because of metabolic, hereditary, or viral etiologies⁴³⁻⁴⁵. Expanded oxidant worry in the islets may likewise add to A-β+ KPD. In one investigation of West African patients, X-connected glucose-6-phosphate dehydrogenase (G6PD) insufficiency added to discouraged beta cell protection against oxidant worry notwithstanding intense hyperglycemia, however its cause does not seem, by all accounts, to be a hereditary change⁴⁶.

4. NORMAL HISTORY OF KPD SYNDROMES

The characteristic history of KPD after the underlying scene of DKA relies on the nearness of autoantibodies and long haul beta cell save. Long haul beta cell hold is the key determinant of long haul glycemic control and insulin reliance^{47,48}.

The characteristic history of KPD is best point by point in huge associates with longitudinal follow-up^{3,11,12,23,41}. One of the biggest of these companions, the Houston partner, incorporates 185 multiethnic grown-ups patients conceded with DKA somewhere around 1999 and 2001 and took after for a mean of 5.5 years. The most successive KPD subgroup was A-β+ (54 percent), trailed by A-β-, A+β-, and A+β+ representing 20, 18, and 8 percent of patients, separately⁴¹.

The A+β- and A-β- KPD patients showed a common course of finish insulin reliance and trouble in accomplishing and accomplishing amazing long haul glycemic control. Despite the fact that there was no distinction in the mean age of the patients conceded with DKA amid study enrollment, there were critical gathering contrasts in mean age at diabetes conclusion and term of diabetes (table 1). Contrasted with patients with the A-β+ and A+β+ phenotypes, patients with the A+β- and A-β-phenotypes were analyzed at a before age (around 25 versus 40 years) and had a more extended term of diabetes (roughly nine versus two years).

The dominant part of A+β+ KPD patients had new onset diabetes. Not long after determination of DKA, around 50 percent of patients had satisfactory beta cell practical hold and could suspend insulin; the others remain insulin subordinate (table 1).

Around 50 percent of A-β+ KPD patients had new-onset diabetes and created DKA without a clinically clear encouraging element ("unjustifiable" A-β+ KPD), while the rest of had long-standing diabetes preceding presentation with DKA, and created ketoacidosis in relationship with intense disease or resistance with antidiabetic treatment ("incited" A-β+ KPD).

Unjustifiable A-β+ KPD patients showed a striking male transcendence (2.6:1, male:female) that is very unmistakable from incited A-β+ KPD patients (0.7:1); this sex awkwardness has been noted additionally in patients with the ridiculous A-β+ KPD phenotype in different accomplices^{11,23,49}.

Longitudinal information recommend other phenotypic contrasts between the unmerited and incited subgroups of A-β+ KPD patients. Imminent appraisal of 83 unmerited and 64 incited A-β+ KPD patients uncovered that in spite of proportionate degrees of hyperglycemia and beta cell utilitarian save at introductory testing taking after the file DKA scene, the two subgroups had distinctive hereditary attributes, normal histories of beta cell capacity, and insulin necessities⁵⁰. Ridiculous A-β+ KPD was described by reversible beta-cell brokenness with male power and expanded recurrence of DQB1*0602, though incited A-β+ KPD was portrayed by dynamic loss of beta-cell hold and expanded recurrence of DQB1*0302 and DRB1*04. In this forthcoming appraisal, unwarranted DKA anticipated long haul beta-cell practical save, insulin autonomy, and glycemic control in KPD patients⁵¹. In a study, a Caucasian patient with such qualities (have against GAD, hostile to IA2 and against insulin negative autoantibodies yet as often as possible in blend with HLA class II at hazard for type 1 DM (DRB1*03 and/or DRB1*04), in whom it was conceivable to pull back insulin treatment⁵²⁻⁵⁴.

In a littler accomplice investigation of patients with new-onset unmerited DKA, beta cell utilitarian hold was safeguarded in a more prominent extent of large contrasted and incline patients^{11,12}. In another accomplice study with 10-year development, KPD patients with the likely A-β+ phenotype (ridiculous) at first accomplished insulin autonomy and glycemic control with oral specialists²³. Toward the end of the subsequent period, 40 percent were still insulin autonomous. In those that required insulin, the mean term until backslide to insulin reliance was 40 months. Some of these patients experienced backsliding and transmitting ketosis.

5. UNCOMMON CONTEMPLATIONS

As portrayed prior, A-β+ KPD patients might be separated into another onset "unjustifiable" gathering (giving DKA without critical anxiety) and a formerly analyzed "incited" bunch (DKA connected with huge anxiety). Patients in the previous subgroup have a fundamentally more prominent rate of insulin end and preferable long haul glycemic control over the last mentioned. New onset diabetes, more seasoned age at onset of diabetes, and elevated amounts of beta cell utilitarian hold (fasting C-peptide to glucose proportion >11) might be utilized as solid indicators of insulin suspension in β+ patients^{48,55-57}. In a multivariate model, new onset diabetes and beta cell useful hold stayed prescient.

The nearness of beta cell autoantibodies is a determinant of future beta cell work. In examinations that don't separate the four Aβ subgroups, KPD patients with autoantibodies have a tendency to have bring down beta cell work both soon after the adjustment of the acidosis and on long haul follow-up^{18,23}. In any case, this is not a trustworthy measure, as around 50 percent of A+β+ KPD patients keep up long haul beta cell utilitarian save. Most A+β+ KPD patients can fall off insulin treatment at first, however they require close observing for no less than two years, since the advancement of their beta cell capacity is the slightest unsurprising of the KPD bunches. HLA writing may assume a valuable part in the administration of this gathering of KPD patients, as it might distinguish the individuals who are probably going to encounter a more forceful course or might be possibility for future immunomodulatory treatment⁵⁸.

6. CONCLUSION

KPD is a heterogeneous disorder described by the nearness of diabetic ketoacidosis in patients who may do not have the ordinary clinical phenotype of immune system type 1 diabetes. Acknowledgment of KPD corresponds with the rise of the idea that early beta cell brokenness is probably going to be an essential deformity in the pathophysiology of diabetes, paying little heed to "type." Although appropriate epidemiologic reviews stay to be led, disorders of KPD give off an impression of being progressively perceived around the world, particularly among urban, multiethnic populaces. They offer difficulties to both clinicians and specialists, additionally offer the possibility of uncovering novel systems of beta cell brokenness important to regular types of diabetes.

Competing Interests:

None of the authors has any competing interests.

REFERENCES

- [1] Umpierrez, G. E., Smiley, D. & Kitabchi, A. E. Narrative review: ketosis-prone type 2 diabetes mellitus. *Ann. Intern. Med.* 144, 350–357 (2006).
- [2] Vaibhav, A., Mathai, M. & Gorman, S. Atypical diabetes in children: ketosis-prone type 2 diabetes. *Case Reports* 2013, bcr2012007704-bcr2012007704 (2013).
- [3] Balasubramanyam, A., Nalini, R., Hampe, C. S. & Maldonado, M. Syndromes of Ketosis-Prone Diabetes Mellitus. *Endocr. Rev.* 29, 292–302 (2008).
- [4] Maldonado, M. et al. Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functional classification, prospective analysis, and clinical outcomes. *J. Clin. Endocrinol. Metab.* 88, 5090–8 (2003).
- [5] Balasubramanyam, A. et al. Accuracy and predictive value of classification schemes for ketosis-prone diabetes. *Diabetes Care* 29, 2575–9 (2006).
- [6] Dodu, S. R. Diabetes in the tropics. *Br. Med. J.* 2, 747–50 (1967).
- [7] Kwaku Adadevoh, B. ‘Temporary diabetes’ in adult Nigerians. *Trans. R. Soc. Trop. Med. Hyg.* 62, 528–530 (1968).
- [8] Oli, J. M. Remittant diabetes mellitus in Nigeria. *Trop. Geogr. Med.* 30, 57–62 (1978).
- [9] Winter, W. E. et al. Maturity-onset diabetes of youth in black Americans. *N. Engl. J. Med.* 316, 285–91 (1987).
- [10] Banerji, M. A. et al. GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4. *Flatbush diabetes.* *Diabetes* 43, 741–5 (1994).
- [11] Umpierrez, G. E. et al. Diabetic ketoacidosis in obese African-Americans. *Diabetes* 44, 790–795 (1995).
- [12] Umpierrez, G. E. et al. Immunogenetic analysis suggests different pathogenesis for obese and lean African-Americans with diabetic ketoacidosis. *Diabetes Care* 22, 1517–1523 (1999).
- [13] Aizawa, T. et al. Ketoacidosis-onset noninsulin dependent diabetes in Japanese subjects. *Am. J. Med. Sci.* 310, 198–201 (1995).
- [14] Wilson, C., Krakoff, J. & Gohdes, D. Ketoacidosis in Apache Indians with non-insulin-dependent diabetes mellitus. *Arch. Intern. Med.* 157, 2098–100 (1997).
- [15] Pinhas-Hamiel, O., Dolan, L. M. & Zeitler, P. S. Diabetic ketoacidosis among obese African-American adolescents with NIDDM. *Diabetes Care* 20, 484–486 (1997).
- [16] Balasubramanyam, A., Zern, J. W., Hyman, D. J. & Pavlik, V. New profiles of diabetic ketoacidosis: type 1 vs type 2 diabetes and the effect of ethnicity. *Arch. Intern. Med.* 159, 2317–22 (1999).
- [17] Westphal, S. A. The occurrence of diabetic ketoacidosis in non-insulin-dependent diabetes and newly diagnosed diabetic adults. *Am. J. Med.* 101, 19–24 (1996).
- [18] Piñero-Piloña, A., Litonjua, P., Aviles-Santa, L. & Raskin, P. Idiopathic type 1 diabetes in Dallas, Texas: a 5-year experience. *Diabetes Care* 24, 1014–8 (2001).
- [19] Pitteloud, N. & Philippe, J. Characteristics of Caucasian type 2 diabetic patients during ketoacidosis and at follow-up. *Schweiz. Med. Wochenschr.* 130, 576–582 (2000).
- [20] Jabbar, a et al. Clinical characteristics and outcomes of diabetic ketoacidosis in Pakistani adults with Type 2 diabetes mellitus. *Diabet. Med.* 21, 920–3 (2004).
- [21] Tan, K. C. B., Mackay, I. R., Zimmet, P. Z., Hawkins, B. R. & Lam, K. S. L. Metabolic and immunologic features of Chinese patients with atypical diabetes mellitus. *Diabetes Care* 23, 335–8 (2000).

International Journal of Novel Research in Healthcare and Nursing

 Vol. 4, Issue 1, pp: (12-18), Month: January - April 2017, Available at: www.noveltyjournals.com

- [22] Sobngwi, E., Mauvais-Jarvis, F., Vexiau, P., Mbanya, J. C. & Gautier, J. F. Diabetes in Africans. Part 2: Ketosis-prone atypical diabetes mellitus. *Diabetes Metab.* 28, 5–12 (2002).
- [23] Mauvais-Jarvis, F. et al. Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance. *Diabetes* 53, 645–53 (2004).
- [24] Stephen, M. D., Gungor, N. & Douty, D. R. Type 2 diabetes mellitus in a young girl: ominous presentation and atypical course. *J. Pediatr. Endocrinol. Metab.* 25, 577–580 (2012).
- [25] Khan, K. A. & Akram, J. South Asian version of flatbush diabetes mellitus- A case report and review article. *J. Med. Med. Sci.* 1, 347–352 (2009).
- [26] Mayer-Davis, E. J. et al. Diabetes in African American Youth: Prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. *Diabetes Care* 32, S112–S122 (2009).
- [27] Imran, S. A. & Ur, E. Atypical ketosis-prone diabetes. *Can. Fam. Physician* 54, 1553–4 (2008).
- [28] Sapru, A. et al. Prevalence and characteristics of type 2 diabetes mellitus in 9-18 year-old children with diabetic ketoacidosis. *J. Pediatr. Endocrinol. Metab.* 18, 865–872 (2005).
- [29] Pietropaolo, M., Barinas-Mitchell, E., Pietropaolo, S. L., Kuller, L. H. & Trucco, M. Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. *Diabetes* 49, 32–8 (2000).
- [30] Naik, R. G., Brooks-Worrell, B. M. & Palmer, J. P. Latent Autoimmune Diabetes in Adults. *J. Clin. Endocrinol. Metab.* 94, 4635–4644 (2009).
- [31] Kobayashi, T. Subtype of insulin-dependent diabetes mellitus (IDDM) in Japan: slowly progressive IDDM--the clinical characteristics and pathogenesis of the syndrome. *Diabetes Res. Clin. Pract.* 24 Suppl, S95-9 (1994).
- [32] Nalini, R., Maldonado, M. & Balasubramanyam, A. A comparison of classification schemes for ketosis-prone diabetes. *Nat. Clin. Pract. Endocrinol. Metab.* 3, E1–E1 (2007).
- [33] McCormack, S. & Grant, S. F. A. Genetics of Obesity and Type 2 Diabetes in African Americans. *J. Obes.* 2013, 1–12 (2013).
- [34] Umpierrez, G. E. Ketosis-Prone Type 2 Diabetes: Time to revise the classification of diabetes. *Diabetes Care* 29, 2755–2757 (2006).
- [35] Hampe, C. S. et al. Association of amino-terminal-specific antiglutamate decarboxylase (GAD65) autoantibodies with beta-cell functional reserve and a milder clinical phenotype in patients with GAD65 antibodies and ketosis-prone diabetes mellitus. *J. Clin. Endocrinol. Metab.* 92, 462–7 (2007).
- [36] Wenzlau, J. M. et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. *Proc. Natl. Acad. Sci. U. S. A.* 104, 17040–5 (2007).
- [37] Kasimiotis, H. et al. Antibodies to SOX13 (ICA12) are associated with type 1 diabetes. *Autoimmunity* 33, 95–101 (2001).
- [38] Decochez, K. et al. High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry. *Diabetes Care* 23, 838–44 (2000).
- [39] Borg, H., Gottsäter, A., Fernlund, P. & Sundkvist, G. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. *Diabetes* 51, 1754–62 (2002).
- [40] Rowley, M. J., Mackay, I. R., Chen, Q. Y., Knowles, W. J. & Zimmet, P. Z. Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus. *Diabetes* 41, 548–551 (1992).
- [41] Nalini, R. et al. HLA Class II Alleles Specify Phenotypes of Ketosis-Prone Diabetes. *Diabetes Care* 31, 1195–1200 (2008).

International Journal of Novel Research in Healthcare and Nursing

 Vol. 4, Issue 1, pp: (12-18), Month: January - April 2017, Available at: www.noveltyjournals.com

- [42] Haaland, W. C. et al. A-beta-subtype of ketosis-prone diabetes is not predominantly a monogenic diabetic syndrome. *Diabetes Care* 32, 873–7 (2009).
- [43] Umpierrez, G. E., Smiley, D., Gosmanov, A. & Thomason, D. Ketosis-prone type 2 diabetes: effect of hyperglycemia on beta-cell function and skeletal muscle insulin signaling. *Endocr Pr.* 13, 283–290 (2007).
- [44] Mauvais-Jarvis, F. et al. PAX4 gene variations predispose to ketosis-prone diabetes. *Hum. Mol. Genet.* 13, 3151–3159 (2004).
- [45] Sobngwi, E. et al. Ketosis-prone type 2 diabetes mellitus and human herpesvirus 8 infection in sub-saharan africans. *JAMA* 299, 2770–2776 (2008).
- [46] Sobngwi, E. et al. High prevalence of glucose-6-phosphate dehydrogenase deficiency without gene mutation suggests a novel genetic mechanism predisposing to ketosis-prone diabetes. *J. Clin. Endocrinol. Metab.* 90, 4446–51 (2005).
- [47] Maldonado, M. et al. Predictors of glycaemic control in indigent patients presenting with diabetic ketoacidosis. *Diabetes. Obes. Metab.* 7, 282–9 (2005).
- [48] Maldonado, M. R., Otiniano, M. E., Cheema, F., Rodriguez, L. & Balasubramanyam, A. Factors associated with insulin discontinuation in subjects with ketosis-prone diabetes but preserved beta-cell function. *Diabet. Med.* 22, 1744–1750 (2005).
- [49] Piñero-Piloña, A. & Raskin, P. Idiopathic Type 1 diabetes. *J. Diabetes Complications* 15, 328–35 (2001).
- [50] Nalini, R. et al. Presence or absence of a known diabetic ketoacidosis precipitant defines distinct syndromes of ‘A-β+’ ketosis-prone diabetes based on long-term β-cell function, human leukocyte antigen class II alleles, and sex predilection. *Metabolism.* 59, 1448–55 (2010).
- [51] Howarth, D. Ketoacidosis in a patient with type 2 diabetes - flatbush diabetes. *Aust. Fam. Physician* 44, 53–4 (2015).
- [52] Rodacki, M. et al. Relato de caso: diabetes Flatbush - da cetoacidose ao tratamento não-farmacológico. *Arq. Bras. Endocrinol. Metabol.* 51, 131–135 (2007).
- [53] Jha, S., Waghdhare, S., Siddiqui, S., Srivastava, K. & Bhargava, A. First Identification of Flatbush Diabetes in Patients of Indian Origin. *Diabetes Care* 38, e164–e165 (2015).
- [54] Colloby, M. Ketosis-prone diabetes: Identification and management. *J. Diabetes Nurs.* 18, 352–360 (2014).
- [55] Sobngwi, E. et al. Metabolic and immunogenetic prediction of long-term insulin remission in African patients with atypical diabetes. *Diabet. Med.* 19, 832–5 (2002).
- [56] Hsin Yu, E., Guo, H. R. & Wu, T. J. Factors associated with discontinuing insulin therapy after diabetic ketoacidosis in adult diabetic patients. *Diabet. Med.* 18, 895–9 (2001).
- [57] Rasouli, N. & Elbein, S. C. Improved glycemic control in subjects with atypical diabetes results from restored insulin secretion, but not improved insulin sensitivity. *J. Clin. Endocrinol. Metab.* 89, 6331–5 (2004).
- [58] Wang, X. & Tan, H. Male predominance in ketosis-prone diabetes mellitus (Review). *Biomed. Reports* 3, 439–442 (2015).